RxDoctor Payments Data

Adriana Ruiz

Medical · Atlanta, GANPI 1386997039

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (44.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Sequel Med Tech, LLC accounts for 60.1% of it on its own, with 45 other manufacturers making up the rest. 2025 is the largest year on record at $26,155, 9.4 times the $2,796 reported in 2021. Among medical clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$38,626in general payments, 2019–2025

Across 633 payments — averaging $61.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sequel Med Tech, LLC$23K
  • Novo Nordisk$3K
  • Amgen$1K
  • Lilly USA, LLC$1K
  • Corcept Therapeutics$1K
  • Sanofi-aventis U.S. LLC$814
  • plus $8K from 40 others

What the payments were for

  • Consulting fees$17,08444%
  • Travel & lodging$5,13713%
  • Food & beverage$16,25642%
  • Education$1510%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,626 in reported general payments places this provider in the 95th percentile of 950 medical providers in Georgia.

See all medical providers in Georgia

Most prescribed under Part D

DrugClaimsCost to plans & patients
KorlymMifepristone17$1,152,444
OzempicSemaglutide241$367,818
JardianceEmpagliflozin79$103,804
MounjaroTirzepatide41$78,401
FarxigaDapagliflozin Propanediol39$47,170
Tresiba Flextouch U-100Insulin Degludec51$28,051
JanuviaSitagliptin Phosphate14$18,051
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog25$17,990
Fiasp FlextouchInsulin Aspart (Niacinamide)15$15,317
Nano 2nd Gen Pen NeedlePen Needle, Diabetic119$14,716
AfrezzaInsulin Regular, Human11$14,353
Tresiba Flextouch U-200Insulin Degludec16$13,886
Lantus SolostarInsulin Glargine,hum.Rec.Anlog76$11,208
NovologInsulin Aspart26$7,540
Humalog Kwikpen U-100Insulin Lispro26$6,195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Corcept TherapeuticsKorlym$1,233$1,152,44417 claims
Novo NordiskOzempic, Novolog$2,621$375,357267 claims
Boehringer IngelheimJardiance$397$103,80479 claims
Lilly USA, LLCMounjaro$1,389$78,40141 claims
AstraZenecaFarxiga$414$47,17039 claims
MerckJanuvia$41$18,05114 claims
Mannkind CorporationAfrezza$626$14,35311 claims
AbbVieSynthroid$45$1,79113 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$554$67372 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 950 medical providers in Georgia.

Other medical in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →